Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability
Authors:
- 5 January 2012
- journal article
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series C: Applied Statistics
- Vol. 61 (2) , 219-235
Abstract
Summary: We propose a randomized phase II clinical trial design based on Bayesian adaptive randomization and predictive probability monitoring. Adaptive randomization assigns more patients to a more efficacious treatment arm by comparing the posterior probabilities of efficacy between different arms. We continuously monitor the trial using the predictive probability. The trial is terminated early when it is shown that one treatment is overwhelmingly superior to others or that all the treatments are equivalent. We develop two methods to compute the predictive probability by considering the uncertainty of the sample size of the future data. We illustrate the proposed Bayesian adaptive randomization and predictive probability design using a phase II lung cancer clinical trial, and we conduct extensive simulation studies to examine the operating characteristics of the design. By coupling adaptive randomization and predictive probability approaches, the trial can treat more patients with a more efficacious treatment and allow for early stopping whenever sufficient information is obtained to conclude treatment superiority or equivalence. The design proposed also controls both the type I and the type II errors and offers an alternative Bayesian approach to the frequentist group sequential design.Keywords
Funding Information
- Research Grants Council of Hong Kong, the US National Institutes of Health (CA16672, CA97007)
- M. D. Anderson University Cancer Foundation (80094548)
This publication has 26 references indexed in Scilit:
- Adaptive Clinical Trials: The Promise and the CautionJournal of Clinical Oncology, 2011
- Outcome-Adaptive Randomization: Is It Useful?Journal of Clinical Oncology, 2011
- Selection and bias—Two hostile brothersStatistics in Medicine, 2009
- Optimising the design of phase II oncology trials: The importance of randomisationEuropean Journal of Cancer, 2009
- Response-Adaptive Randomization for Survival Trials: The Parametric ApproachJournal of the Royal Statistical Society Series C: Applied Statistics, 2007
- Practical Bayesian adaptive randomisation in clinical trialsEuropean Journal of Cancer, 2007
- Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future DirectionsJournal of Clinical Oncology, 2005
- A unified method for monitoring and analysing controlled trialsStatistics in Medicine, 1994
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961